Farydak

(panobinostat)

Uses, side effects, dosage information & price range

pharmaand GmbH

About this medicine

Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent. Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.

Common Substitutes & Alternatives

These medicines share the same salt composition or therapeutic category and can be used as substitutes under professional medical supervision.

PoherdyComposition: pertuzumabOrganon N.V.

Price on RequestView Details →

MekinistComposition: trametinibNovartis Europharm Limited

Price on RequestView Details →

VijoiceComposition: alpelisibNovartis Europharm Limited

Price on RequestView Details →

KisqaliComposition: ribociclibNovartis Europharm Limited

Price on RequestView Details →

TecartusComposition: brexucabtagene autoleucelKite Pharma EU B.V.

Price on RequestView Details →

Key Information

Salt / Composition

panobinostat